Sunday, April 26, 2015

Celladon says heart treatment fails in trial

NEW YORK (Reuters) - Celladon Corp said its heart failure gene therapy Mydicar failed to meet its primary and secondary endpoints in an important trial.Read more

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.